TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 03/11/25

2025-03-11 16:00:09 ET Summary Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, s...

2025-01-31 08:30:00 ET Summary Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 earnings, raised full-year FY2025 guidance, and announced a n...

2025-01-30 17:03:15 ET Summary On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again. So, sales of its oncology franchise reached $5.5 billion, an increase of 19% compared to the fourth quarter of 2023. ...

2025-01-30 16:45:35 ET More on Takeda Pharmaceutical, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors Takeda gains af...

2025-01-30 16:45:14 ET Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Results Conference Call January 30, 2025 05:30 AM ET Company Participants Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Mi...

2025-01-30 01:49:20 ET More on Takeda Pharmaceutical: Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors Ascentage Pharma raises $126M via U.S. IPO (update) Takeda-backed Ascentage Pharma sets terms for $170M IPO Seek...

2025-01-23 13:36:22 ET Summary AstraZeneca is one of the fastest-growing players among Big Pharma. The company's significant balance sheet strengthening in recent years has been driven by the rapid expansion of its portfolio of FDA-approved drugs, particularly those targeting canc...

2025-01-19 16:54:45 ET Summary This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regu...

2025-01-13 05:55:13 ET Summary Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertid...

2025-01-09 15:56:43 ET Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continue...